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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.001Cyclins encode regulatory subunits of holoenzymes that phosphorylate a variety of cellular substrates.
Although the classic role of cyclins in cell cycle progression and tumorigenesis has been well charac-
terized, new functions have been identiﬁed, including the induction of cellular migration and invasion,
enhancement of angiogenesis, inhibition of mitochondrial metabolism, regulation of transcription factor
signaling via a DNA-bound form, the induction of chromosomal instability, enhancement of DNA damage
sensing and DNA damage repair, and feedback governing expression of the noncoding genome. This
review describes the mechanisms of these new functions of cyclin D1. (Am J Pathol 2013, 183: 3e9;
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sibility for analyses, interpretations, or conclusions.The family of D-type cyclins (D1, D2, and D3) regulates the
G1/S-phase transition, and D cyclins bind and activate cyclin-
dependent kinases (Cdk4 and Cdk6) to phosphorylate the
retinoblastoma (pRb) protein, and through titration of the
Cdk inhibitors p21Cip1 and p27Kip1, the cyclin DeCdk4/6
complexes activate cyclin E/Cdk2.1 Genetic analysis studies in
mice have demonstrated an essential role for cyclin D1 in
normal development of the retina, components of the nervous
system, and terminal alveolar breast bud development.2,3
Cyclin D1 promotes neural basal progenitors,4 and use of
a kinase-deﬁcient cyclin D1 cDNA (K112E) deﬁned an
important role for CDK activity in the self-renewal properties
of mammary epithelial cell progenitors.5 Cyclin E can partially
rescue the retinal and mammary epithelial cell developmental
abnormalities likely related to the progenitor pool expansion.6
The kinase-defective cyclin D1 K112E binds p27Kip1, and, in
conjunction with prior studies showing p27Kip1, is epistemic to
cyclin D1 in the development of the retina and mammary
epithelial cell proliferation, raises the possibility of a role for
p27Kip1 binding in this stem cell differentiation function.7
Studies of cyclin D1/ bone marrow macrophages
demonstrated an essential role for cyclin D1 in cellular adhe-
sion and migration, a ﬁnding common to other cell types,
including ﬁbroblasts andmammary epithelial cells.8e10 Cyclin
D1b, a common polymorphism at the exon-4 intron-4
boundary of the human cyclin D1 gene, did not enhance cell
migration.11 The mechanism by which cyclin D1a promotesstigative Pathology.
.cell migration has been examined in detail. Cyclin D1a
stabilizes p27Kip1, inhibiting RhoA-inducing Rho-associated
protein kinase and myosin light chain kinase.9e11 Cyclin D1
also conveys an indirect effect to inhibit migration by inhib-
iting epithelial-mesenchymal transition,12 suggesting the effect
of cyclin D1 on migration may vary by cell type and differ-
entiation status.12 Mass spectrometry identiﬁed protein kinase
C and casein kinase substrate in neurons 213 and ﬁlamin A13 as
additional factors involved in cyclin D1emediated migration.
The effects of cyclin D1 to promote migration were observed
in cyclin D1/ cells that express cyclin D1 and cyclin A3;
thus, the function appears to be speciﬁc to cyclin D1, which
was necessary and sufﬁcient for the promigratory function.
Cyclin D1 Inhibits Mitochondrial Metabolism by
Phosphorylating NRF-1
Cyclin D1 deﬁciency in cells and in vivo is associated with
increased mitochondrial size and activity (Figure 1).14,15
PestellRescue of the cyclin D1/ cells’ mitochondrial phenotype
required the Cdk function of cyclin D1. Nuclear respiratory
factor 1 (NRF-1), which induces expression of nuclear-
encoded mitochondrial genes, was repressed in expression
and activity by cyclin D1, which phosphorylated NRF-1 at
S47 (Figure 1A).14 By using cyclin D1 antisense mammary
epithelial targeted transgenic mice, the role for cyclin D1 as an
inhibitor of mitochondrial biogenesis and activity was
conﬁrmed in vivo. Endogenous cyclin D1was shown to inhibit
mitochondrial biogenesis and activity by gene expression
signaling and in vivo imaging. Consistent with these ﬁndings,
cyclin D1einduced mammary tumors showed inhibition of
mitochondrial activity and aerobic glycolysis with enhanced
cytosolic glycolysis.15 In vivomeasurements of relative use of
amino acids from the tricarboxylic acid cycle using nuclear
magnetic resonance in cyclin D1/ mammary epithelium
showed changes in the ratio of glutamate and glutamine/
citrate, associated with the induction of mitochondrialFigure 1 Cyclin D1 inhibits mitochondrial biogenesis. A: Schematic
representation of the mechanism by which cyclin D1 inhibits mitochondrial
function. Cyclin D1edependent kinase phosphorylates and inhibits NRF-1
and, thereby, mitochondrial transcription factor A and mitochondrial
activity. B: Cyclin D1 deﬁciency enhances mitochondrial size and function.
Transmission electron microscopic images of hepatocytes from liver tissue
of cyclin D1þ/þ (red box, enlarged area) and cyclin D1/ (yellow box,
enlarged area) show increased mitochondria size in cyclin D1/. Catalase-
positive peroxisomes (dark spherical structures) are evident. Original
magniﬁcation, 5000 (right column).
4metabolism and reduced cytosolic glycolysis, and the gluta-
mate plus glutamine/citrate ratio was increased.15 A similar
change in cellular metabolism was observed in the mammary
epithelium of ponasterone-inducible cyclin D1 antisense
transgenic mice.15 Cyclin D1 was also shown to inhibit
mitochondrial function through binding to the mitochondrial
voltage-dependent anion channel, thereby competing with
hexokinase II.16 The cyclin D1emediated inhibition of NRF-1
and, thereby mitochondrial transcription factor A, to reduce
mitochondrial activity was observed in cells expressing
cyclin E.
Cyclin E is regulated by mitochondrial activity in that
disruption of the mitochondrial electron transport chain acti-
vates a G1/S checkpoint that degrades cyclin E.
17 Consistent
with these ﬁndings, pRb was subsequently shown to couple
cell cycle exit with mitochondrial biogenesis.18 Inactivation of
pRb, or p21 overexpression, also inhibits mitochondrial
metabolism, thereby increasing cytosolic glycolysis, suggest-
ing the effect of cyclinD1 is part of a broader role for the cyclin
D1/Rb/CDK inhibitor pathway. Collectively, these studies
demonstrated that increased abundance of cyclin D1 deter-
mines metabolic substrate prioritization toward amino acid
synthesis from the tricarboxylic acid cycle, consistent with
a known role for cyclin D1 in the induction of DNA synthesis
and the known induction of cytosolic glycolysis in tumors.
Whether the cyclin D1edependent inhibition ofmitochondrial
biogenesis contributes to the glucose avidity of carcinomas
remains to be determined.
Cyclin D1 Governs Transcription Factor Activity
and Gene Expression by Recruiting Chromatin
Remodeling Proteins to the Coding and
Noncoding Genome
More than 35 distinct transcription factors are regulated by
cyclin D1 expression.19 The mechanism appears to involve
recruitment to DNA of transcription factors and associated
chromatin-modifying enzymes.19 By using cyclin D1/
mice, it was shown that cyclin D1 plays a critical role in the
recruitment of transcription factors in the context of local
chromatin to their cognate DNA-binding site.20 Peroxisome
proliferator-activated receptor (PPAR)g recruitment to the
murine lipoprotein lipase promoter, characterized in chro-
matin immunoprecipitation (ChIP) assays, was dependent on
the relative abundance of endogenous cyclin D1. These
original studies by Hulit et al20 demonstrated the essential
role for cyclin D1 in the recruitment of transcription factors in
the context of local chromatin. Although it was known that
cyclin D1 inhibited PPARg reporter gene activity in a Cdk-
independent manner, and that endogenous cyclin D1
played an important role in fat metabolism in vivo, these
studies by Hulit and coworkers,21 were the ﬁrst to demon-
strate the critical role for cyclin D1 in recruiting a transcrip-
tion factor to target genes in vivo. Subsequent studies using
ChIP analysis provided a framework demonstrating thatajp.amjpathol.org - The American Journal of Pathology
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target genes. Fu et al22 conducted ChIP analysis of cyclin
D1/mouse embryo ﬁbroblasts (MEFs), demonstrating that
the recruitment of cyclin D1, in turn, recruited PPARg,
histone deacetylase (HDAC), and HDAC3 in the context of
local chromatin. Fu et al22,23 showed that the recruitment of
cyclin D1 was associated with the corecruitment of Su (Var)
39H1 and heterochromatin protein 1a (Figure 2) and an
induction of dimethylation of H3K9.
Cyclins E and D regulate transcription factor activity
through several mechanisms.24 First, CDK activity regulates
the function of a variety of transcription factors, including
p53, E2 transcription factor, B lymphoma Mo-MLV insertion
region 1 homolog, and inhibitor of DNA-binding protein 2, in
a Cdk-dependent manner. In addition, cyclins regulate the
activity of the basal transcription apparatus and co-activators.
Thus, the RNA polymerase II large subunit contains the
essential carboxyl terminal domain, which is phosphorylated
by the general transcription factor, TFIIH. The co-activator
proteins p300/calcium-binding protein (CBP) undergo phos-
phorylation during the cell cycle, and the activity of p300 is
directly regulated by cyclin D1.23 The repression of p300 by
cyclin D1 involved distinct domains from those regulated by
p21Cip1. Recent studies demonstrated the association of p300/
CBP with cyclin D1 and the co-occupancy of p300 and
cyclin D1 in the context of local chromatin using ChIP-ChIP
on a 5.5- to 2.5-kb ChIP-ChIP microarray containing
approximately 17,000 genes. At the p21Cip1/Waf1 promoter,
cyclin D1 reduced the recruitment of CBP,25 whereas cyclin
D1 enhanced recruitment of the related p300 to the murineFigure 2 Schematic representation of cyclin D1 interactions. Schematic repres
shown as either CDK independent or unknown.
The American Journal of Pathology - ajp.amjpathol.orgLPL promoter,23 suggesting cyclin D1 conveys gene-speciﬁc
co-integrator recruitment function. Cyclin D1 inhibits p300-
mediated acetylation of histones and autoacetylation,
providing an alternative mechanism by which cyclin D1 may
regulate gene transcription (Figure 2).23 In addition to
binding histone acetyltransferases (p300, CBP, and p300/
CBP-associated factor)26,27 to regulate histone acetylation
and histone deacetylases,28 cyclin D1 also recruits the
estrogen receptor (ER)a co-activator, AIB1, to enhance ERa
activity at a synthetic estrogen-responsive element.29,30
Cyclin D1 phosphorylates methylosome protein 50 and
thereby increases activity of PRMT5, a histone arginine
methyltransferase.31 Recent studies identiﬁed approximately
132 cyclin D1einteractive proteins,32 which included several
previously identiﬁed cyclin D1ebinding proteins (RAD51,
HDAC, and p27), but did not identify other recently identiﬁed
proteins, PRMT533 or C/EBP,34 suggesting cell typeespeciﬁc
effects. BRCA proteins were shown to bind cyclin D1,32
consistent with prior studies. In prior studies, BRCA1 colo-
calized in nuclear foci with RAD51 and RAD50, and cyclin
D1 and BRCA1 formed distinct complexes with ERa in breast
cancer cells.35 The well documented inhibition of ERa activity
by BRCA136e39 was reversed by cyclin D1, requiring an
HLH-like region between residues 141 and 178 (Figure 2).20
Cyclin D1 expression enhanced ERa recruitment in the
context of local chromatin to an estrogen-responsive element
in ChIP assays, and cyclin D1 interacted with ERa and
BRCA1 at the pS2 gene promoter.
ChIP-ChIP and ChIP-Sequencing analyses have revealed
the complexity of genomic binding by the DNA-associatedentation of functions shown to involve CDK binding with other interactions
5
Pestellform of cyclin D1. ChIP of cyclin D1, followed by ChIP-
Sequencing, mapped at high resolution the entire genomic
region bound by cyclin D1. The genome-wide distribution
of binding sites in relation to the transcriptional start site
showed that peak values of active regions within the
promoter are comparable to those at 10 kb and beyond,
suggesting that cyclin D1 localizes to both promoter-
proximal elements and distant elements (Figure 2). The
transcription factorebinding sites enriched in the cyclin D1
peak interval sequences of ChIP-ChIP identiﬁed several top
hit transcription factors that correlated in function with the
previous studies by Sicinski using promoter ChIP analysis,
including mitochondrial metabolism, cellular division, and
RNA processing (Figure 2). The cis elements included Ctcf,
Zfx, Sp1, Mizf, Esr1, ERa, E2f1, and Creb1. Subsequent
studies identiﬁed cyclin D3 in ChIP at PPARg target
promoters, much like cyclin D1.40 The ability of cyclins to
regulate transcription factor activity is not restricted to
cyclin D1, although the mechanisms appear to differ; thus,
cyclin E/CDK2 phosphorylates TF (NFKB, inhibitor of
DNA-binding protein 2, and AR) and coactivators (CBP and
p220NPAT) to regulate their activity.41Figure 3 Hypothetical functional interaction between cyclin D1 as a kinase
complex, which phosphorylates pRb and NRF1, and the DNA-bound form, which
binds promoters of genes regulating CIN, to promote oncogenesis.Cyclin D1 Rapidly Induces CIN and Binds in
ChIP to a Cluster of Genes Governing CIN
Functional pathway analysis of the gene-regulatory elements
bound by cyclin D1 uncovered enrichment for genes that
govern chromosomal stability and demonstrated, by ChIP,
occupancy of cyclin D1 at the regulatory regions of several
genes involved in chromosomal stability.42 The DNA
sequences associated with cyclin D1 enrichment included
Ctcf, Zfx, Sp1, Mizf, Esr1, and E2F1. The enrichment for
E2f1 was signiﬁcantly less, and the P value for E2f1 was two
orders of magnitude less than that for Esr1 (ERa) and three
orders of magnitude less than that for Ctcf. These ﬁndings
suggest that cyclin D1edependent regulation of E2f1
signaling, which is Cdk dependent,43 provides only a modest
contribution to this signaling activity. Chromosomal insta-
bility (CIN) in tumors is characterized by chromosomal
abnormalities and an altered gene expression signature. CIN
in tumors is characterized by an elevated rate of gain or loss
of whole chromosomes (aneuploidy) and/or structural chro-
mosomal aberrations.44e46 One of the most striking differ-
ences between cancer and normal cells is aneuploidy. The
molecular mechanisms inducing CIN in tumors are poorly
understood.47,48 Cell cycleeassociated factors have been
implicated in CIN, including cyclin E.49 The relative
enrichment of a molecular genetic signature of CIN-related
genes has been used to quantitate a CIN score,50 including
AURKB, TOP2A, CENPP, MLF1IP, ZW10, and CKAP2.46
Interrogation of gene expression from 2254 breast tumors
identiﬁed cyclin D1 expression correlating with CIN in
luminal B breast cancer (Figure 2).42 Cyclin D1 rescue of
cyclin D1/ MEFs induced CIN gene expression and CIN6gene-regulatory region occupancy by the DNA-bound form
of cyclin D1. Mammary glandetargeted cyclin D1 expres-
sion induced tumors with CIN, and short-term transgenic
expression of cyclin D1 induced CIN in vivo.
Previous studies had characterized a function for cyclin E
in regulating the centrosome. The in vivo analysis of E-type
cyclins identiﬁed a key role for cyclin E in re-entry to the
cell cycle from the quiescent state, and in cultured cells,
centrosomal localization of cyclin E was required for
S-phase entry in a Cdk2-independent manner.51,52 Cyclin E
overexpression also induces CIN in tumors thought to be
related to the induction of double-standard DNA breaks.53Cyclin D1 Governs DNA Damage Repair through
Recruiting DNA Repair Complexes
Cell typeedependent radiationeinduced sensitivity is
determined by the relative abundance of cyclin D1. Gamma
irradiationeinduced apoptosis was enhanced in cyclin D1/
MEFs,54 and cyclin D1 expression inhibited UV-induced
apoptosis in a p300-dependent manner. In contrast, breast
cancer cell lines show enhanced apoptosis in response to g
radiation when cyclin D1 is overexpressed.55,56 Cyclin D1 is
important in G1 cell arrest in response to gamma irradi-
ationeinduced DNA damage because interference in cyclin
D1 degradation prevents both G1 arrest and G2-M arrest
induced by gamma irradiation.57 Intriguingly, lymphoid
compartmentetargeted transgenic expression of a cyclin D1
mutant (D1T286A) that is nuclear in expression during S
phase induced aneuploidy lymphoid tumors in which a DNA
damage response (DDR) was triggered.31
Because a physical tethering of DNA repair factors to
chromatin induces the DDR signaling cascade, and cyclin
D1 is recruited to local chromatin, as evidenced by ChIP
assays, Li et al61 examined the role of cyclin D1 in regu-
lating the DNA damage signaling response. By using the
comet assay, in which intact DNA composes the head,
and the tail consists of damaged DNA at a neutral pH,
cyclin D1þ/þ had a 14-fold increase in comet tail formationajp.amjpathol.org - The American Journal of Pathology
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on serine 139 (gH2A), a sensitive mark of double-strand
breaks, was increased with doxorubicin treatment in cyclin
D1þ/þ compared with cyclin D1/ cells. Cyclin D1 siRNA
mediated reduction in endogenous cyclin D1 and reduced
5-ﬂuorouracileinduced gH2A phosphorylation. The enhan-
cement of the DDR by cyclin D1 occurred rapidly (15
minutes), preceding the effect on DNA synthesis (>6
hours). Cyclin D1a enhanced the DDR induced by doxo-
rubicin but did not enhance S-phase entry in the absence of
serum, providing corroborative evidence that the induction
of the DDR by cyclin D1a can be uncoupled from the
induction of DNA synthesis. Cyclin D1 was shown to bind
p21Cip1 and RAD51 using a cherry red ﬂuorescent LacR
reporter system and immune precipitation. By using p21/
MEFs, cyclin D1 induction of the DDR was shown to
require p21Cip1. Cyclin D1a recapitulated the recruitment of
H2AX at the LacO site in a similar manner as the DNA
damage repair signaling pathway proteins ATM, NBS1, or
MDC1. Mutational analysis demonstrated a requirement for
the cyclin D1 carboxyl terminus in the recruitment to H2AX
foci. Cyclin D1a was shown to recruit RAD51 in the context
of local chromatin in response to the DNA damage.
The induction of RAD51 abundance by cyclin D1a, its
binding to cyclin D1a, and recruitment by cyclin D1 in the
context of chromatin to sites of DNA damage support the
notion that cyclin D1 enhances the DDR, but does not
formally determine its role in DNA damage repair. Cyclin
D1a induces genes involved in DNA replication and/or the
DNA damage checkpoint in ﬁbroblasts and in the mammary
epithelium.15,22 A protein interaction analysis of cyclin
D1einteracting proteins identiﬁed RAD51.32 By using
a homologous recombination repair reporter system,
endogenous cyclin D1 was shown to increase the homolo-
gous recombination rate. BRCA2 was also identiﬁed as
a cyclin D1einteracting protein, and BRCA2 knockdown
reduced cyclin D1 recruitment to DNA damage sites. Cyclin
D1 depletion did not affect BRCA2 recruitment. However,
cyclin D1 depletion reduced RAD51 recruitment to DNA
damage sites.32 Again, the regulation of DNA replication
and/or DNA damage checkpoints is not unique to cyclin D1.
Cyclin D1 induces the expression of minichromosome
maintenance-deﬁcient (MCM) 2, MCM3, and MCM4,
15,23
whereas cyclin E/CDK regulates loading of MCM onto
chromatin52 through both kinase-dependent and kinase-
independent mechanisms.58
Collectively, these studies illustrate the diverse roles that
cyclin D1 plays, including the inhibition of mitochondrial
biogenesis through phosphorylation of NRF-1, inhibition of
G1/S-phase transition through phosphorylation of pRb, and
the regulation of gene expression, at least in part through
a DNA-bound form of cyclin D1 that interacts with tran-
scription factors in the context of chromatin (Figure 3). The
mechanisms by which each of these functions contributes to
oncogenesis and stem cell function remain to be fully
understood.The American Journal of Pathology - ajp.amjpathol.orgFuture Directions: Cyclin D1 Regulates the
Noncoding Genome
At this time, relatively little is known of the mechanisms by
which the cell cycle and cyclins regulate the noncoding
genome. miRNAs are 21- to 22-nucleotide molecules that
regulate cellular phenotype via regulation of translational
efﬁciency or the stability of targeted mRNAs. Compelling
evidence has demonstrated the importance of the noncoding
genome and the miRNA biogenesis apparatus in tumori-
genesis. Analysis of miRNAs regulated in cyclin D1e
induced transgenic mammary tumors and those reciprocally
regulated in cyclin D1 antisense or knockout mice identiﬁed
the miR-17/20 cluster as a cyclin D1einduced regulator of
mammary tumor growth. miR-17/20 repressed cyclin D1
expression via its 30 untranslated region binding site.59 In
ChIP assays, cyclin D1 associated with the miR-17/20
regulatory region between nucleotides 1050 and 1200.
To our knowledge, these studies were the ﬁrst to demon-
strate cyclin-dependent regulation of noncoding RNA via
binding to the regulatory region of the noncoding miRNA
cluster. Yu et al60 demonstrated that miR-17/20 expression
regulated the secretion of cytokines and plasminogen acti-
vator via expression of a-enolase and cytokeratin 8. The
inhibition of plasminogen activator by miR-17/20 required
cyclin D1, indicating that complex regulatory loops between
the noncoding and coding genome govern cellular migration
of breast cancer cells.60
At this time, published studies suggest cyclin E is regu-
lated by several different miRNAs, including miR-223, miR-
161, and miR-195. However, there is no evidence that cyclin
E binds to regulatory regions of the noncoding genome to
coordinate miRNA expression. As yet, there is no clear
mechanism by which the cell cycle coordinates signaling of
noncoding RNA biogenesis. Given the disruption of non-
coding genome precursors in many tumors, it will be of
particular interest to determine the potential role for cyclins
in regulating broader aspects of noncoding RNA biogenesis.References
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